Fortrea Holdings (FTRE) Return on Capital Employed (2023 - 2026)
Fortrea Holdings (FTRE) posted Return on Capital Employed of 20.1% for Q1 2026, up 58.17% on a QoQ basis from 48.06% in Q4 2025, and up 732.0% year-over-year from 2.42% in Q1 2025.
Fortrea Holdings (FTRE) Return on Capital Employed (2023 - 2026) Analysis & Trends
Fortrea Holdings' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 20.1% for Q1 2026.
- Quarterly Return on Capital Employed rose 732.0% year-over-year to 20.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.1% (up 732.0% YoY) and the FY2025 annual result came in at 39.06%, down 3367.0% from the prior year.
- Return on Capital Employed was 20.1% for Q1 2026 at Fortrea Holdings, up from 48.06% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1.97% in Q3 2023 and bottomed at 48.8% in Q3 2025.
- A 4-year average of 18.31% and a median of 6.06% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 4418 bps — and 2026, when it soared 732 bps.
- Fortrea Holdings' Return on Capital Employed stood at 0.9% in 2023, then tumbled by 771 bps to 6.06% in 2024, then tumbled by 693 bps to 48.06% in 2025, then soared by 58 bps to 20.1% in 2026.
- Business Quant data shows FTRE's Return on Capital Employed at 20.1% in Q1 2026, 48.06% in Q4 2025, and 48.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Fortrea Holdings | 1.79 Bn | 1.64 Bn | 123.60 Mn | -20.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.10% |
| Dec 31, 2025 | -48.06% |
| Sep 30, 2025 | -48.80% |
| Jun 30, 2025 | -45.39% |
| Mar 31, 2025 | -27.42% |
| Dec 31, 2024 | -6.06% |
| Sep 30, 2024 | -4.62% |
| Jun 30, 2024 | -3.23% |
| Mar 31, 2024 | -0.56% |
| Dec 31, 2023 | 0.90% |
| Sep 30, 2023 | 1.97% |